Laporan Laba Rugi (TTM)
Laporan Laba Rugi Y-Biologics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2020 12-31 |
2021 12-31 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,731 | 4,847 | 4,151 | 3,598 | 2,593 | 3,536 | 3,479 | 4,077 | 3,998 | 5,231 | 5,763 | 5,027 | 5,960 |
| Change (%) | -27.99 | -14.37 | -13.32 | -27.93 | 36.36 | -1.60 | 17.19 | -1.95 | 30.87 | 10.16 | -12.76 | 18.55 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 1,059 | 2,528 | 2,895 | 2,745 | 2,035 | 1,576 | 1,141 | 990 | 1,119 | 1,202 | 1,495 | 1,273 | 1,173 |
| Change (%) | 138.72 | 14.53 | -5.18 | -25.88 | -22.57 | -27.59 | -13.26 | 13.03 | 7.47 | 24.40 | -14.85 | -7.89 | |
| % of Revenue | 15.73 | 52.15 | 69.75 | 76.31 | 78.48 | 44.57 | 32.79 | 24.27 | 27.98 | 22.98 | 25.95 | 25.33 | 19.68 |
| Gross Operating Profit | 5,673 | 2,319 | 1,255 | 852 | 558 | 1,960 | 2,338 | 3,088 | 2,879 | 4,029 | 4,267 | 3,754 | 4,787 |
| Change (%) | -59.11 | -45.88 | -32.10 | -34.55 | 251.32 | 19.29 | 32.05 | -6.75 | 39.96 | 5.91 | -12.03 | 27.52 | |
| % of Revenue | 84.27 | 47.85 | 30.25 | 23.69 | 21.52 | 55.43 | 67.21 | 75.73 | 72.02 | 77.02 | 74.05 | 74.67 | 80.32 |
| SG&A | 3,417 | 5,143 | 5,556 | 10,194 | 5,945 | 4,894 | 4,974 | 5,104 | 4,771 | 5,034 | 5,005 | 4,785 | 4,128 |
| Change (%) | 50.52 | 8.04 | 83.49 | -41.69 | -17.67 | 1.63 | 2.62 | -6.52 | 5.51 | -0.58 | -4.39 | -13.73 | |
| % of Revenue | 50.76 | 106.09 | 133.86 | 283.35 | 229.27 | 138.43 | 142.97 | 125.20 | 119.36 | 96.23 | 86.85 | 95.19 | 69.27 |
| R&D | 8,860 | 12,589 | 11,941 | 5,020 | 5,020 | 4,693 | 6,650 | 6,524 | 8,157 | 8,681 | 6,828 | 6,368 | 6,160 |
| Change (%) | 42.08 | -5.14 | -57.96 | 0.00 | -6.52 | 41.71 | -1.89 | 25.02 | 6.43 | -21.34 | -6.74 | -3.26 | |
| % of Revenue | 131.62 | 259.70 | 287.71 | 139.53 | 193.60 | 132.72 | 191.14 | 160.02 | 204.04 | 165.94 | 118.49 | 126.66 | 103.36 |
| OpEx | 14,764 | 22,212 | 22,981 | 20,395 | 15,435 | 13,452 | 13,622 | 12,574 | 14,259 | 14,839 | 14,210 | 13,299 | 12,265 |
| Change (%) | 50.45 | 3.46 | -11.25 | -24.32 | -12.85 | 1.26 | -7.69 | 13.40 | 4.07 | -4.24 | -6.41 | -7.78 | |
| % of Revenue | 219.32 | 458.23 | 553.68 | 566.88 | 595.28 | 380.45 | 391.53 | 308.41 | 356.69 | 283.66 | 246.58 | 264.54 | 205.78 |
| Operating Income | -8,032 | -17,365 | -18,830 | -16,797 | -12,842 | -9,916 | -10,143 | -8,497 | -10,261 | -9,608 | -8,447 | -8,272 | -6,305 |
| Change (%) | 116.19 | 8.44 | -10.80 | -23.55 | -22.78 | 2.29 | -16.23 | 20.76 | -6.37 | -12.08 | -2.07 | -23.78 | |
| % of Revenue | -119.32 | -358.23 | -453.68 | -466.88 | -495.28 | -280.45 | -291.53 | -208.41 | -256.69 | -183.66 | -146.58 | -164.54 | -105.78 |
| Interest Expense | -446 | -115 | -103 | -126 | -126 | -150 | -144 | -92 | -94 | -79 | -43 | -31 | -37 |
| Change (%) | -74.29 | -9.84 | 21.75 | -0.00 | 19.20 | -4.23 | -35.74 | 1.31 | -15.44 | -45.75 | -27.54 | 18.41 | |
| % of Revenue | -6.63 | -2.37 | -2.49 | -3.50 | -4.86 | -4.25 | -4.13 | -2.27 | -2.34 | -1.51 | -0.75 | -0.62 | -0.62 |
| Net Income | -10,029 | -17,071 | -18,804 | -16,385 | -12,684 | -9,430 | -20,871 | -18,760 | -19,627 | -19,238 | -6,442 | -6,699 | -6,192 |
| Change (%) | 70.22 | 10.15 | -12.86 | -22.59 | -25.65 | 121.32 | -10.11 | 4.62 | -1.98 | -66.52 | 4.00 | -7.57 | |
| % of Revenue | -148.98 | -352.17 | -453.06 | -455.44 | -489.18 | -266.71 | -599.90 | -460.13 | -490.96 | -367.73 | -111.78 | -133.25 | -103.90 |
Source: Capital IQ
